CA3032124A1 - Gpr156 variants and uses thereof - Google Patents

Gpr156 variants and uses thereof Download PDF

Info

Publication number
CA3032124A1
CA3032124A1 CA3032124A CA3032124A CA3032124A1 CA 3032124 A1 CA3032124 A1 CA 3032124A1 CA 3032124 A CA3032124 A CA 3032124A CA 3032124 A CA3032124 A CA 3032124A CA 3032124 A1 CA3032124 A1 CA 3032124A1
Authority
CA
Canada
Prior art keywords
nucleic acid
seq
gpr156
acid sequence
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3032124A
Other languages
English (en)
French (fr)
Inventor
Claudia GONZAGA-JAUREGUI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CA3032124A1 publication Critical patent/CA3032124A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
CA3032124A 2016-07-28 2017-07-28 Gpr156 variants and uses thereof Pending CA3032124A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662367973P 2016-07-28 2016-07-28
US62/367,973 2016-07-28
PCT/US2017/044321 WO2018022967A1 (en) 2016-07-28 2017-07-28 Gpr156 variants and uses thereof

Publications (1)

Publication Number Publication Date
CA3032124A1 true CA3032124A1 (en) 2018-02-01

Family

ID=59649989

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3032124A Pending CA3032124A1 (en) 2016-07-28 2017-07-28 Gpr156 variants and uses thereof

Country Status (13)

Country Link
US (4) US10266582B2 (cg-RX-API-DMAC7.html)
EP (2) EP4230648A3 (cg-RX-API-DMAC7.html)
JP (2) JP7556688B2 (cg-RX-API-DMAC7.html)
KR (2) KR102661616B1 (cg-RX-API-DMAC7.html)
CN (1) CN109563516B (cg-RX-API-DMAC7.html)
AU (1) AU2017302611B2 (cg-RX-API-DMAC7.html)
CA (1) CA3032124A1 (cg-RX-API-DMAC7.html)
DK (1) DK3491014T5 (cg-RX-API-DMAC7.html)
IL (1) IL264473A (cg-RX-API-DMAC7.html)
MX (2) MX2019001084A (cg-RX-API-DMAC7.html)
NZ (1) NZ751010A (cg-RX-API-DMAC7.html)
SG (1) SG11201900738YA (cg-RX-API-DMAC7.html)
WO (1) WO2018022967A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201900738YA (en) * 2016-07-28 2019-02-27 Regeneron Pharma Gpr156 variants and uses thereof
CN111373053B (zh) 2017-09-06 2024-07-30 雷杰纳荣制药公司 单免疫球蛋白白介素-1受体相关分子(sigirr)变体及其用途
DK3505157T3 (da) 2017-12-29 2022-02-28 Celon Pharma Sa Tørpulver-ketaminsammensætning til pulmonal indgivelse ved behandlingsresistent depression
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
SG11202106423PA (en) * 2019-01-17 2021-07-29 Regeneron Pharma A rodent model of mood disorders

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5294533A (en) 1988-07-05 1994-03-15 Baylor College Of Medicine Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria
US5135917A (en) 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
US5271941A (en) 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
US5786138A (en) 1993-01-29 1998-07-28 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Hyperstabilizing antisense nucleic acid binding agents
DE69425890D1 (de) 1993-06-04 2000-10-19 Us Health Verfahren zur behandlung von kaposi-sarcoma mit antisense-oligonukleotide
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US5641754A (en) 1994-01-10 1997-06-24 The Board Of Regents Of The University Of Nebraska Antisense oligonucleotide compositions for selectively killing cancer cells
WO1996005298A1 (en) 1994-08-09 1996-02-22 Ciba-Geigy Ag Antitumor antisense oligonucleotides
US5856103A (en) 1994-10-07 1999-01-05 Board Of Regents The University Of Texas Method for selectively ranking sequences for antisense targeting
US5994320A (en) 1995-02-06 1999-11-30 Regents Of The University Of Minnesota Antisense oligonucleotides and methods for treating central nervous system tumors
IT1275862B1 (it) 1995-03-03 1997-10-24 Consiglio Nazionale Ricerche Trascritto antisenso associato ad alcuni tipi di cellule tumorali ed oligodeossinucleotidi sintetici utili nella diagnosi e nel trattamento
US6040296A (en) 1995-06-07 2000-03-21 East Carolina University Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
AU7286696A (en) 1995-10-13 1997-05-07 F. Hoffmann-La Roche Ag Antisense oligomers
CN1202900A (zh) 1995-11-21 1998-12-23 Icn药品公司 用il-8和il-8受体的反义寡核苷酸抑制肿瘤生长
WO1997029757A1 (en) 1996-02-15 1997-08-21 National Institutes Of Health Rnase l activators and antisense oligonucleotides effective to treat rsv infections
US5955590A (en) 1996-07-15 1999-09-21 Worcester Foundation For Biomedical Research Conjugates of minor groove DNA binders with antisense oligonucleotides
US6046004A (en) 1997-02-27 2000-04-04 Lorne Park Research, Inc. Solution hybridization of nucleic acids with antisense probes having modified backbones
JPH1142091A (ja) 1997-07-25 1999-02-16 Toagosei Co Ltd アンチセンス核酸化合物
US6046319A (en) 1997-10-22 2000-04-04 University Technologies International, Inc. Antisense oligodeoxynucleotides regulating expression of TNF-α
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
US6007995A (en) 1998-06-26 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of TNFR1 expression
US6013522A (en) 1999-02-23 2000-01-11 Isis Pharmaceuticals Inc. Antisense inhibition of human Smad1 expression
US6025198A (en) 1999-06-25 2000-02-15 Isis Pharmaceuticals Inc. Antisense modulation of Ship-2 expression
WO2001004137A1 (en) * 1999-07-09 2001-01-18 Genaissance Pharmaceuticals, Inc. Drug target isogenes: polymorphisms in the osteoclastogenesis inhibitory factor gene
US6033910A (en) 1999-07-19 2000-03-07 Isis Pharmaceuticals Inc. Antisense inhibition of MAP kinase kinase 6 expression
WO2001079230A2 (en) * 2000-04-18 2001-10-25 Genaissance Pharmaceuticals, Inc. Haplotypes of the ugt1a1 gene
EP1581648A2 (en) 2002-09-09 2005-10-05 Nura, Inc. G protein coupled receptors and uses thereof
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
EP1745018A1 (en) * 2004-04-29 2007-01-24 Merck & Co., Inc. Azetidine glycine transporter inhibitors
EP2091556B1 (en) 2006-11-15 2018-07-25 Omeros Corporation Non-human animal comprising a mutation in the sreb2/gpr85 gene as animal model of metabolic disease
CN104583402A (zh) * 2012-05-16 2015-04-29 Rana医疗有限公司 用于调节mecp2表达的组合物和方法
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
DK3363902T3 (da) 2012-12-06 2020-01-02 Sigma Aldrich Co Llc Crispr-baseret genommodifikation og -regulering
US20200276110A1 (en) * 2015-12-21 2020-09-03 Bayer Oy A method of manufacturing a vaginal ring
SG11201900738YA (en) 2016-07-28 2019-02-27 Regeneron Pharma Gpr156 variants and uses thereof

Also Published As

Publication number Publication date
US20220073589A1 (en) 2022-03-10
KR20240027874A (ko) 2024-03-04
DK3491014T3 (da) 2023-05-30
MX2019001084A (es) 2019-06-10
KR20190034532A (ko) 2019-04-02
MX2024013403A (es) 2024-12-06
WO2018022967A1 (en) 2018-02-01
EP4230648A3 (en) 2023-10-18
US10266582B2 (en) 2019-04-23
US20190202891A1 (en) 2019-07-04
US10562953B2 (en) 2020-02-18
JP2023071704A (ja) 2023-05-23
AU2017302611B2 (en) 2021-12-09
DK3491014T5 (da) 2024-09-02
CN109563516A (zh) 2019-04-02
US20180030114A1 (en) 2018-02-01
SG11201900738YA (en) 2019-02-27
US20200231651A1 (en) 2020-07-23
CN109563516B (zh) 2023-10-27
AU2017302611A1 (en) 2019-03-14
IL264473A (en) 2019-02-28
JP7556688B2 (ja) 2024-09-26
KR102661616B1 (ko) 2024-04-30
NZ751010A (en) 2024-11-29
US11155598B2 (en) 2021-10-26
JP2019527229A (ja) 2019-09-26
EP3491014B1 (en) 2023-04-05
EP4230648A2 (en) 2023-08-23
EP3491014A1 (en) 2019-06-05

Similar Documents

Publication Publication Date Title
US11155598B2 (en) GPR156 variants and uses thereof
US20220017964A1 (en) Cornulin (CRNN) Variants And Uses Thereof
HK40098517A (en) Gpr156 variants and uses thereof
US20210230609A1 (en) Solute Carrier Family 14 Member 1 (SLC14A1) Variants And Uses Thereof
JP7237064B2 (ja) 単一免疫グロブリンインターロイキン-1受容体関連(sigirr)変異型及びその使用
RU2815068C2 (ru) Варианты белка, родственного рецептору интерлейкина-1 и содержащего одиночный домен иммуноглобулина (sigirr), и их применение
HK40033837B (en) Single immunoglobulin interleukin-1 receptor related (sigirr) variants and uses thereof
HK40033837A (en) Single immunoglobulin interleukin-1 receptor related (sigirr) variants and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220629

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240925

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250127

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260116

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260316

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260703